<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03402230</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2017-02406</org_study_id>
    <secondary_id>NCI-2017-02406</secondary_id>
    <secondary_id>N01-CN-2012-00031</secondary_id>
    <secondary_id>1711022046</secondary_id>
    <secondary_id>UAZ2017-09-02</secondary_id>
    <secondary_id>N01CN00031</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <nct_id>NCT03402230</nct_id>
  </id_info>
  <brief_title>Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers</brief_title>
  <official_title>Clinical Study of AvmacolÂ® for Detoxification of Tobacco Carcinogens in Heavy Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized early phase I trial studies how well broccoli sprout/broccoli seed extract&#xD;
      supplement works in decreasing toxicity in heavy smokers. Broccoli sprout/broccoli seed&#xD;
      extract supplement is a dietary supplement made from broccoli sprout and seed extract powder,&#xD;
      and may break down some of the cancer causing substances in tobacco smoke and produce&#xD;
      substances that may protect cells from tobacco smoke-induced damage in current smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether broccoli sprout/broccoli seed extract supplement (Avmacol) increases&#xD;
      the urinary excretion of the mercapturic acid of the tobacco carcinogen, benzene, in healthy&#xD;
      volunteers who are current heavy smokers.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether Avmacol increases the urinary excretion of the mercapturic acids of&#xD;
      other tobacco carcinogens, including acrolein and crotonaldehyde.&#xD;
&#xD;
      II. To determine whether Avmacol increases the urinary excretion of the mercapturic acids of&#xD;
      tobacco carcinogens, normalized by bio-measurement of tobacco exposure.&#xD;
&#xD;
      III. To determine whether Avmacol upregulates the NRF2 target gene transcripts in the buccal&#xD;
      cells of current smokers.&#xD;
&#xD;
      IV. To evaluate for a dose-response relationship between Avmacol and the detoxification of&#xD;
      tobacco carcinogens and the expression of NRF2 target gene transcripts.&#xD;
&#xD;
      V. To determine the relationship between systemic study agent exposure and biomarker&#xD;
      modulation.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether the GSTM1 and GSTT1 genotypes are important genetic modulators of&#xD;
      detoxification of tobacco carcinogens with Avmacol treatment.&#xD;
&#xD;
      II. To bank specimens for future research including evaluation of tobacco gene signatures in&#xD;
      buccal and nasal epithelium and buccal cell nuclear morphometry.&#xD;
&#xD;
      OUTLINE: Participants are randomized into 1 of 2 arms.&#xD;
&#xD;
      ARM I: Participants receive lower dose broccoli sprout/broccoli seed extract supplement&#xD;
      orally (PO) daily for 10-14 days. After 10-14 days, participants receive higher dose broccoli&#xD;
      sprout/broccoli seed extract supplement PO daily for 10-14 days.&#xD;
&#xD;
      ARM II: Participants receive higher dose broccoli sprout/broccoli seed extract supplement PO&#xD;
      daily for 10-14 days. After 10-14 days, participants receive lower dose broccoli&#xD;
      sprout/broccoli seed extract supplement PO daily for 10-14 days.&#xD;
&#xD;
      After completion of study, participants are followed up at 10-14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">January 10, 2022</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urinary Excretion of the Mercapturic Acid of Benzene Following 4 Tablets of Broccoli Sprout/Broccoli Seed Extract Per Day</measure>
    <time_frame>Baseline up to 14 days post intervention</time_frame>
    <description>Change (from baseline to post intervention) in the overnight urinary excretion the mercapturic acid of benzene, normalized by urinary creatinine concentration, following 4 tablets of broccoli sprout/broccoli seed extract per day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urinary Excretion of the Mercapturic Acid of Benzene Following 8 Tablets of Broccoli Sprout/Broccoli Seed Extract Per Day</measure>
    <time_frame>Baseline up to 14 days post intervention</time_frame>
    <description>Change (from baseline to post intervention) in the overnight urinary excretion the mercapturic acid of benzene, normalized by urinary creatinine concentration, following 8 tablets of broccoli sprout/broccoli seed extract per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the Urinary Excretion of the Mercapturic Acids of Acrolein and Crotonaldehyde</measure>
    <time_frame>Baseline up to 14 days post intervention</time_frame>
    <description>The changes following 4 tablets of broccoli sprout/broccoli seed extract per day and after 8 tablets of broccoli sprout/broccoli seed extract l per day will be determined separately. Two-sided paired t tests will be performed to evaluate whether the changes are significantly. Bonferroni correction will be used to correct for multiple comparisons (two dose levels).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Excretion of the Mercapturic Acids of Tobacco Carcinogens</measure>
    <time_frame>Up to 14 days post intervention</time_frame>
    <description>Will determine whether broccoli sprout/broccoli seed extract supplement increases the urinary excretion of the mercapturic acids of tobacco carcinogens, normalized by bio-measurement of tobacco exposure. Bio-measurement of tobacco exposure will be assessed by the total urinary levels of nicotine and major nicotine metabolites (i.e., the sum of the molar concentrations of nicotine and major nicotine metabolites in urine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the NRF2 Target Gene Transcripts</measure>
    <time_frame>Baseline up to 14 days post intervention</time_frame>
    <description>Will be assessed by the expression of NQO1, in the buccal cells after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detoxification of Tobacco Carcinogens</measure>
    <time_frame>Up to 14 days post intervention</time_frame>
    <description>Will determine whether there is a dose-response relationship between the broccoli sprout/broccoli seed extract supplement dose and the detoxification of tobacco carcinogens and the change in the NRF2 target gene transcripts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Study Agent Exposure</measure>
    <time_frame>Up to 14 days post intervention</time_frame>
    <description>Will determine the relationship between systemic study agent exposure, assessed by the total urinary levels of sulforaphane and its glutathione-derived metabolites (i.e., the sum of the molar concentrations of sulforaphane and its glutathione-derived metabolites in urine), and changes in detoxification of tobacco carcinogens and NRF2 target gene transcripts.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>GSTM1 and GSTT1 Genotypes</measure>
    <time_frame>Up to 14 days post intervention</time_frame>
    <description>Will determine whether the GSTM1 and GSTT1 genotypes are important genetic modulators of detoxification of tobacco carcinogens. The change in the urinary excretion of the mercapturic acids of tobacco carcinogens will be compared between GSTM1-null and GSTM1 positive subjects and between GSTT1-null and GSTT1-positive subjects.</description>
  </other_outcome>
  <other_outcome>
    <measure>Specimen Banking</measure>
    <time_frame>Up to 14 days post intervention</time_frame>
    <description>Will bank specimens for future research including tobacco gene signature in nasal brushing, and fixed buccal cells for nuclear morphometry.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Cigarette Smoking-Related Carcinoma</condition>
  <condition>Tobacco-Related Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (Avmacol lower dose, Avmacol higher dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (Avmacol higher dose, Avmacol lower dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Broccoli Sprout/Broccoli Seed Extract Supplement</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (Avmacol lower dose, Avmacol higher dose)</arm_group_label>
    <arm_group_label>Arm II (Avmacol higher dose, Avmacol lower dose)</arm_group_label>
    <other_name>Avmacol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (Avmacol lower dose, Avmacol higher dose)</arm_group_label>
    <arm_group_label>Arm II (Avmacol higher dose, Avmacol lower dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (Avmacol lower dose, Avmacol higher dose)</arm_group_label>
    <arm_group_label>Arm II (Avmacol higher dose, Avmacol lower dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current tobacco smokers with &gt;= 20 pack years of self-reported smoking exposure and a&#xD;
             current average use of &gt;= 10 cigarettes/day&#xD;
&#xD;
          -  Karnofsky performance scale &gt;= 70%&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/microliter&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/microliter&#xD;
&#xD;
          -  Platelets &gt;= 100,000/microliter&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 x institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Creatinine =&lt; ULN&#xD;
&#xD;
          -  Fertile subjects must use adequate contraception (abstinence, barrier methods, or&#xD;
             birth control pills) prior to study entry and for the duration of study participation;&#xD;
             women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation; should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her study physician&#xD;
             immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of invasive cancer within the past 2 years, with the exception of excised and&#xD;
             cured non-melanoma skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Chronic, current or recent (within the past 2 weeks) use of systemic steroid doses&#xD;
             equivalent to prednisone &gt; 5 mg daily for continued use &gt; 14 days; use of inhaled&#xD;
             steroids, nasal sprays, and topical creams for small body areas is allowed&#xD;
&#xD;
          -  Participants may not be receiving any other investigational agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Avmacol&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie E Bauman</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Arizona Medical Center-University Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner University Medical Center - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center - Prevention Research Clinic</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <results_first_submitted>February 2, 2021</results_first_submitted>
  <results_first_submitted_qc>March 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2021</results_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03402230/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Avmacol Low Dose First, Then High Dose</title>
          <description>Participants received lower dose of Avmacol daily for 10-14 days, followed by 10-14 days of washout, and followed by higher dose of Avmacol daily for 10-14 days.</description>
        </group>
        <group group_id="P2">
          <title>Avmacol High Dose First, Then Low Dose</title>
          <description>Participants received higher dose of Avmacol daily for 10-14 days, followed by 10-14 days of washout, and followed by lower dose of Avmacol daily for 10-14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Avmacol</title>
          <description>Participants who initiated Avmacol intervention</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary Excretion of the Mercapturic Acid of Benzene Following 4 Tablets of Broccoli Sprout/Broccoli Seed Extract Per Day</title>
        <description>Change (from baseline to post intervention) in the overnight urinary excretion the mercapturic acid of benzene, normalized by urinary creatinine concentration, following 4 tablets of broccoli sprout/broccoli seed extract per day</description>
        <time_frame>Baseline up to 14 days post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Avmacol</title>
            <description>Participants who initiated Avmacol intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Excretion of the Mercapturic Acid of Benzene Following 4 Tablets of Broccoli Sprout/Broccoli Seed Extract Per Day</title>
          <description>Change (from baseline to post intervention) in the overnight urinary excretion the mercapturic acid of benzene, normalized by urinary creatinine concentration, following 4 tablets of broccoli sprout/broccoli seed extract per day</description>
          <units>pmol/mg Cr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" lower_limit="-0.79" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary Excretion of the Mercapturic Acid of Benzene Following 8 Tablets of Broccoli Sprout/Broccoli Seed Extract Per Day</title>
        <description>Change (from baseline to post intervention) in the overnight urinary excretion the mercapturic acid of benzene, normalized by urinary creatinine concentration, following 8 tablets of broccoli sprout/broccoli seed extract per day</description>
        <time_frame>Baseline up to 14 days post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Avmacol</title>
            <description>Participants who initiated Avmacol intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Excretion of the Mercapturic Acid of Benzene Following 8 Tablets of Broccoli Sprout/Broccoli Seed Extract Per Day</title>
          <description>Change (from baseline to post intervention) in the overnight urinary excretion the mercapturic acid of benzene, normalized by urinary creatinine concentration, following 8 tablets of broccoli sprout/broccoli seed extract per day</description>
          <units>pmol/mg Cr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="-1.30" upper_limit="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Urinary Excretion of the Mercapturic Acids of Acrolein and Crotonaldehyde</title>
        <description>The changes following 4 tablets of broccoli sprout/broccoli seed extract per day and after 8 tablets of broccoli sprout/broccoli seed extract l per day will be determined separately. Two-sided paired t tests will be performed to evaluate whether the changes are significantly. Bonferroni correction will be used to correct for multiple comparisons (two dose levels).</description>
        <time_frame>Baseline up to 14 days post intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Excretion of the Mercapturic Acids of Tobacco Carcinogens</title>
        <description>Will determine whether broccoli sprout/broccoli seed extract supplement increases the urinary excretion of the mercapturic acids of tobacco carcinogens, normalized by bio-measurement of tobacco exposure. Bio-measurement of tobacco exposure will be assessed by the total urinary levels of nicotine and major nicotine metabolites (i.e., the sum of the molar concentrations of nicotine and major nicotine metabolites in urine).</description>
        <time_frame>Up to 14 days post intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the NRF2 Target Gene Transcripts</title>
        <description>Will be assessed by the expression of NQO1, in the buccal cells after intervention.</description>
        <time_frame>Baseline up to 14 days post intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detoxification of Tobacco Carcinogens</title>
        <description>Will determine whether there is a dose-response relationship between the broccoli sprout/broccoli seed extract supplement dose and the detoxification of tobacco carcinogens and the change in the NRF2 target gene transcripts.</description>
        <time_frame>Up to 14 days post intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Study Agent Exposure</title>
        <description>Will determine the relationship between systemic study agent exposure, assessed by the total urinary levels of sulforaphane and its glutathione-derived metabolites (i.e., the sum of the molar concentrations of sulforaphane and its glutathione-derived metabolites in urine), and changes in detoxification of tobacco carcinogens and NRF2 target gene transcripts.</description>
        <time_frame>Up to 14 days post intervention</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>GSTM1 and GSTT1 Genotypes</title>
        <description>Will determine whether the GSTM1 and GSTT1 genotypes are important genetic modulators of detoxification of tobacco carcinogens. The change in the urinary excretion of the mercapturic acids of tobacco carcinogens will be compared between GSTM1-null and GSTM1 positive subjects and between GSTT1-null and GSTT1-positive subjects.</description>
        <time_frame>Up to 14 days post intervention</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Specimen Banking</title>
        <description>Will bank specimens for future research including tobacco gene signature in nasal brushing, and fixed buccal cells for nuclear morphometry.</description>
        <time_frame>Up to 14 days post intervention</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two weeks of agent intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose</title>
          <description>8 Tablets of Broccoli Sprout/Broccoli Seed Extract Per Day for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Low Dose</title>
          <description>4 Tablets of Broccoli Sprout/Broccoli Seed Extract Per Day for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders, other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sherry Chow, PhD</name_or_title>
      <organization>University of Arizona</organization>
      <phone>5206263358</phone>
      <email>schow@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

